Novavax (NVAX)
(Delayed Data from NSDQ)
$12.53 USD
-0.38 (-2.91%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $12.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NVAX 12.53 -0.38(-2.91%)
Will NVAX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVAX
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax (NVAX) Dips More Than Broader Market: What You Should Know
Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last?
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Other News for NVAX
Novavax price target raised by $3 at B. Riley, here's why
Buy Rating Affirmed for Novavax Amid Strategic Alliances and Promising Vaccine Trials
Novavax gets EU authorization for updated COVID-19 vaccine
Novavax's 2024-2025 Nuvaxovid COVID-19 vaccine receives authorization in EU
Novavax Inc (NVAX) Q2 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...